{"id":"0d678cf5-96a1-5f20-ba6e-687db956a916","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-vegfr2-atp-competition","predicate":"inhibits","statement":"Mebendazole was determined to interfere with vascular endothelial growth factor receptor 2 kinase by competing with ATP, selectively inhibited tumour angiogenesis but not the normal brain vasculature in orthotopic medulloblastoma models, suppressed the kinase in vivo, and significantly extended survival of medulloblastoma models derived from different molecular backgrounds including a PTCH1-mutant tumour with acquired resistance to the smoothened inhibitor vismodegib.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"f7ff30c6-b410-5c0a-8645-dc230b02cbff","mechanism_event_label":"It also blocks the receptor that grows new tumour blood vessels, and spares the normal ones.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"df0e753f-1aca-54a5-9369-d3fcec35613b","slug":"kdr","display_name":"Vascular endothelial growth factor receptor 2 / KDR","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"f7ff30c6-b410-5c0a-8645-dc230b02cbff","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-vegfr2-atp-competition-event","event_type":"biochemical_relationship","label":"It also blocks the receptor that grows new tumour blood vessels, and spares the normal ones.","description":"Mebendazole was determined to interfere with vascular endothelial growth factor receptor 2 kinase by competing with ATP, selectively inhibited tumour angiogenesis but not the normal brain vasculature in orthotopic medulloblastoma models, suppressed the kinase in vivo, and significantly extended survival of medulloblastoma models derived from different molecular backgrounds including a PTCH1-mutant tumour with acquired resistance to the smoothened inhibitor vismodegib.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e771d86a-d95b-520c-a3eb-2f81733eee5d","slug":"tumour-angiogenesis","display_name":"Tumour angiogenesis, as distinguished from normal brain vasculature","entity_type_key":"cellular_process"},"role":"suppressed_process","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9dbb6cfa-50e1-5ff1-8b7e-6d747bf9ad03","slug":"angiogenesis","display_name":"Angiogenesis / new blood vessel formation","entity_type_key":"cellular_process"},"role":"related_process","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"be46a422-4d0b-564a-859d-14f9d7cc4763","slug":"medulloblastoma-growth","display_name":"Growth of medulloblastoma cells and allografts","entity_type_key":"cellular_process"},"role":"affected_process","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"aea6767d-9996-507c-8fb6-c30a983e3d2a","slug":"vismodegib","display_name":"Vismodegib, a Smoothened inhibitor","entity_type_key":"drug"},"role":"resisted_comparator","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"df0e753f-1aca-54a5-9369-d3fcec35613b","slug":"kdr","display_name":"Vascular endothelial growth factor receptor 2 / KDR","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/25253417.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"96333adbb3bce735b14f3c51317229543279992c3cd170760cc494566e49a169\", \"start_char\": 0, \"end_char\": 1798, \"text_sha256\": \"96333adbb3bce735b14f3c51317229543279992c3cd170760cc494566e49a169\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Autophosphorylation and cell-free kinase assays with orthotopic medulloblastoma allograft and xenograft models","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Mebendazole in PTCH1-mutant allografts, a group 3 xenograft and a vismodegib-resistant model","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Identifies a third mechanism, kinase inhibition, with a defined competition mode. Whether this operates at achievable human concentrations is not established here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"It also blocks the receptor that grows new tumour blood vessels, and spares the normal ones.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p25253417] Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. (2015). https://pubmed.ncbi.nlm.nih.gov/25253417/ DOI: 10.1093/neuonc/nou234","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Medulloblastoma and tumour vasculature","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"71a464e0-f584-52ba-aae0-82d8f15d2aba","evidence_kind":"source_excerpt","locator":"Lines 550-561","start_line":550,"end_line":561,"excerpt":"### mbz-vegfr2-atp-competition\nMebendazole was determined to interfere with vascular endothelial growth factor receptor 2 kinase by competing with ATP, selectively inhibited tumour angiogenesis but not the normal brain vasculature in orthotopic medulloblastoma models, suppressed the kinase in vivo, and significantly extended survival of medulloblastoma models derived from different molecular backgrounds including a PTCH1-mutant tumour with acquired resistance to the smoothened inhibitor vismodegib.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: It also blocks the receptor that grows new tumour blood vessels, and spares the normal ones.\norganism: Mouse\ntissue_or_cell_type: Medulloblastoma and tumour vasculature\nexperimental_model: Autophosphorylation and cell-free kinase assays with orthotopic medulloblastoma allograft and xenograft models\nlimitations: Identifies a third mechanism, kinase inhibition, with a defined competition mode. Whether this operates at achievable human concentrations is not established here.\nexposure: Mebendazole in PTCH1-mutant allografts, a group 3 xenograft and a vismodegib-resistant model\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/25253417.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"96333adbb3bce735b14f3c51317229543279992c3cd170760cc494566e49a169\", \"start_char\": 0, \"end_char\": 1798, \"text_sha256\": \"96333adbb3bce735b14f3c51317229543279992c3cd170760cc494566e49a169\"}\n[mbz-p25253417] Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. (2015). https://pubmed.ncbi.nlm.nih.gov/25253417/ DOI: 10.1093/neuonc/nou234","model_system":"Autophosphorylation and cell-free kinase assays with orthotopic medulloblastoma allograft and xenograft models","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p25253417] Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. (2015). https://pubmed.ncbi.nlm.nih.gov/25253417/ DOI: 10.1093/neuonc/nou234","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}